Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of Hydronidone capsules safety in liver fibrosis
CTR20260178Phase 2Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydronidone in hepatic fibrosis, Chronic Hepatitis B (CHB), metabolic dysfunction-associated steatotic liver disease (MASLD) and 1 more, sponsored by Gyre Pharmaceuticals. Primary endpoints: Incidence and severity of adverse events (AEs) and Incidence and severity of serious adverse events (SAEs). Started Mar 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
hepatic fibrosisChronic Hepatitis B (CHB)metabolic dysfunction-associated steatotic liver disease (MASLD)alcoholic liver disease (ALD)
Beyond the preview
Go deeper on CTR20260178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260178.